CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

AbataceptWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug304 Aviptadil by intravenous infusion + standard of care Wiki 0.71
drug1921 Normal Saline Infusion + standard of care Wiki 0.71
drug1607 Losartan Wiki 0.25
drug2122 Placebo Wiki 0.07

Correlated MeSH Terms (8)

Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.14
D055371 Acute Lung Injury NIH 0.13
D012127 Respiratory Distress Syndrome, Newborn NIH 0.13
D012128 Respiratory Distress Syndrome, Adult NIH 0.12
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D003141 Communicable Diseases NIH 0.06
D018352 Coronavirus Infections NIH 0.06
D007239 Infection NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.

NCT04472494 COVID-19 SARS-CoV-2 Biological: Abatacept Other: Placebo

Primary Outcomes

Measure: Proportion of participants with composite end point of mechanical ventilation or death prior to or on Day 28

Time: Up to 28 days

Secondary Outcomes

Measure: Change from baseline in the Ordinal 8-point Outcome Scale on Day 28

Time: Day 28

Measure: All-cause mortality on Day 28

Time: Day 28

Measure: Proportion of participants alive and free of respiratory failure on Day 28

Time: Day 28

Measure: Proportion of participants returned to room air by Day 28

Time: Up to 28 days

Measure: Proportion of participants alive and discharged home by Day 28

Time: Up to 28 days

Measure: Proportion of participants with Serious Adverse Events (SAEs)

Time: Up to 60 days

Measure: Proportion of participants with serious infections

Time: Up to 60 days

2 Abatacept for Patients With COVID-19 and Respiratory Distress

This is a single-arm open label trial for hospitalized patients with COVID-19 (Coronavirus). The primary endpoint of the study is to assess the requirement for mechanical ventilation in patients who are admitted to the hospital with COVID-19 infection and a Pulse Oxygen Level

NCT04477642 COVID-19 Drug: Abatacept

Primary Outcomes

Description: Cumulative incidence of mechanical ventilation-free survival at 30 days after initiation of abatacept

Measure: Mechanical ventilation-free survival

Time: 30 days

Secondary Outcomes

Description: Number of days a patient is on a ventilator, if applicable

Measure: Duration of days on a ventilator

Time: 30 days

Description: Number of days until patient recovers with SpO2 > 93%

Measure: Days until pulse oxygen is > 93% on room air

Time: 30 days

Description: No supplemental oxygen for at least 24 hours

Measure: Days until supplemental oxygen is no longer required

Time: 30 days

Description: Number of days until fever is less than 38°C

Measure: Duration of fever >= 38°C

Time: 30 days

Description: Patient survival status through 90 days

Measure: Overall survival

Time: 90 days

Description: Number of Infusion Reactions in patients treated with abatacept

Measure: Infusion reactions

Time: 14 days

Description: Number of Secondary infections in patients treated with abatacept

Measure: Secondary infections

Time: 90 days

Description: Change in clinical status from baseline, as assessed by a 7-point ordinal scale on Day 14

Measure: Change in Clinical Status, based on 7-point ordinal scale

Time: 14 days

Description: Viral load at baseline and on Days 7, 14, 21, 28 (each +/- 2 days) after the first abatacept dose.

Measure: Viral load

Time: 28 days

Description: Improvement in lung findings based on CXR (chest x-ray)

Measure: Radiographic Improvement

Time: 14 days

No related HPO nodes (Using clinical trials)